Mutational phospho-mimicry reveals a regulatory role for the XRCC4 and XLF C-terminal tails in modulating DNA bridging during classical non-homologous end joining

  1. Davide Normanno
  2. Aurélie Négrel
  3. Abinadabe J de Melo
  4. Stéphane Betzi
  5. Katheryn Meek
  6. Mauro Modesti  Is a corresponding author
  1. Cancer Research Center of Marseille, CNRS UMR7258, Inserm U1068, France
  2. Sigma Aldrich, France
  3. Michigan State University, United States

Abstract

XRCC4 and DNA Ligase 4 (LIG4) form a tight complex that provides DNA ligase activity for classical non-homologous end joining (the predominant DNA double-strand break repair pathway in higher eukaryotes) and is stimulated by XLF. Independently of LIG4, XLF also associates with XRCC4 to form filaments that bridge DNA. These XRCC4/XLF complexes rapidly load and connect broken DNA, thereby stimulating intermolecular ligation. XRCC4 and XLF both include disordered C-terminal tails that are functionally dispensable in isolation but are phosphorylated in response to DNA damage by DNA-PK and/or ATM. Here we concomitantly modify the tails of XRCC4 and XLF by substituting fourteen previously identified phosphorylation sites with either alanine or aspartate residues. These phospho-blocking and -mimicking mutations impact both the stability and DNA bridging capacity of XRCC4/XLF complexes, but without affecting their ability to stimulate LIG4 activity. Implicit in this finding is that phosphorylation may regulate DNA bridging by XRCC4/XLF filaments.

Article and author information

Author details

  1. Davide Normanno

    Cancer Research Center of Marseille, CNRS UMR7258, Inserm U1068, Marseilles, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4740-5542
  2. Aurélie Négrel

    Sigma Aldrich, Saint Quentin Fallavier, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Abinadabe J de Melo

    Cancer Research Center of Marseille, CNRS UMR7258, Inserm U1068, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Stéphane Betzi

    Cancer Research Center of Marseille, CNRS UMR7258, Inserm U1068, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Katheryn Meek

    College of Veterinary Medicine, Michigan State University, East Lansing, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Mauro Modesti

    Cancer Research Center of Marseille, CNRS UMR7258, Inserm U1068, Marseille, France
    For correspondence
    mauro.modesti@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4964-331X

Funding

Fondation ARC pour la Recherche sur le Cancer (SFI20121205867)

  • Mauro Modesti

U.S. Public Health Service (AI048758)

  • Katheryn Meek

Institut National Du Cancer (PLBIO13-099)

  • Mauro Modesti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Barry P Sleckman, Weill Cornell Medical College, United States

Version history

  1. Received: November 2, 2016
  2. Accepted: May 12, 2017
  3. Accepted Manuscript published: May 13, 2017 (version 1)
  4. Version of Record published: June 12, 2017 (version 2)
  5. Version of Record updated: June 13, 2017 (version 3)

Copyright

© 2017, Normanno et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,651
    views
  • 326
    downloads
  • 33
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Davide Normanno
  2. Aurélie Négrel
  3. Abinadabe J de Melo
  4. Stéphane Betzi
  5. Katheryn Meek
  6. Mauro Modesti
(2017)
Mutational phospho-mimicry reveals a regulatory role for the XRCC4 and XLF C-terminal tails in modulating DNA bridging during classical non-homologous end joining
eLife 6:e22900.
https://doi.org/10.7554/eLife.22900

Share this article

https://doi.org/10.7554/eLife.22900

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article

    Mediator of ERBB2-driven Cell Motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Isabelle Petit-Hartlein, Annelise Vermot ... Franck Fieschi
    Research Article

    NADPH oxidases (NOX) are transmembrane proteins, widely spread in eukaryotes and prokaryotes, that produce reactive oxygen species (ROS). Eukaryotes use the ROS products for innate immune defense and signaling in critical (patho)physiological processes. Despite the recent structures of human NOX isoforms, the activation of electron transfer remains incompletely understood. SpNOX, a homolog from Streptococcus pneumoniae, can serves as a robust model for exploring electron transfers in the NOX family thanks to its constitutive activity. Crystal structures of SpNOX full-length and dehydrogenase (DH) domain constructs are revealed here. The isolated DH domain acts as a flavin reductase, and both constructs use either NADPH or NADH as substrate. Our findings suggest that hydride transfer from NAD(P)H to FAD is the rate-limiting step in electron transfer. We identify significance of F397 in nicotinamide access to flavin isoalloxazine and confirm flavin binding contributions from both DH and Transmembrane (TM) domains. Comparison with related enzymes suggests that distal access to heme may influence the final electron acceptor, while the relative position of DH and TM does not necessarily correlate with activity, contrary to previous suggestions. It rather suggests requirement of an internal rearrangement, within the DH domain, to switch from a resting to an active state. Thus, SpNOX appears to be a good model of active NOX2, which allows us to propose an explanation for NOX2’s requirement for activation.